First, multiple hotspot and non-hotspot MAPK mutations (A/BRAF, HRAS, MAPK1, and MAP2K1/2) all abrogated ErbB3 activation, an established signal for HNSCC progression. Here, HRAS is linked to head and neck squamous cell carcinoma.